Why is the Polynovo (ASX:PNV) share price having such a tough time of late?

What’s up with medical device company’s shares? We take a closer look

| More on:
a doctor in a white coat with a stethoscope around her neck holds her hands upwards as if to ask 'why' as she sits at her desk and looks at her computer.

Image source: Getty Images

The Polynovo Ltd (ASX: PNV) share price has been on a trending decline over the past 6 months, falling by 40%. This comes as the medical device company has been relatively quiet on the news front.

At Tuesday’s closing bell, Polynovo shares finished the day up 3.61% to $1.865.

What’s been happening with Polynovo lately?

While no new announcements have been released since last month, Polynovo has been busy progressing its BARDA-funded burn study. BARDA is an acronym for the United States-based Biomedical Advanced Research and Development Authority.

The trial spans 20 United States and 5 Canadian burn centres for the clinical study of NovoSorb BTM. Polynovo aims for its NovoSorb BTM to be used as a standard of care in burn patients.

In addition, the company’s chief operating officer, Dr Anthony Kaye, resigned from his position last month. The Polynovo share price fell more than 10% that week after it was revealed Dr Kaye was returning to CSL Limited (ASX: CSL) in a more senior role.

However, Polynovo’s path to profitability is growing stronger following its robust FY21 results.

The company experienced growth across key financial metrics which led it to break even for the first time in its history.

Polynovo expects continued momentum to run into FY22 across a number of geographical markets. These include the United States, Europe, the United Kingdom, the Middle East, Asia, Australia, and New Zealand.

Its NovoSorb graft is expected to see sales surge in FY22, with “70% of burns centres now having purchased” the product.

Furthermore, Polynovo intends to expand its headcount and enter new markets, particularly within the European Union.

Nonetheless, the Polynovo share price has slumped. This is possibly due to bearish sentiment by investors which has caused selling pressure.

Polynovo share price summary

Despite today’s gain, Polynovo shares are down more than 25% for the past 12 months, and 50% in 2021.

Polynovo has a market capitalisation of roughly $1.24 billion and has approximately 661.4 million shares outstanding.

Should you invest $1,000 in Polynovo right now?

Before you consider Polynovo, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Polynovo wasn't one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares